Virtu Financial’s Grace Therapeutics GRCE Stock Holding History

Virtu Financial’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23K	Buy	+10,166	New	+$28.1K	﹤0.01%	1333
2023 Q2	–	Sell	-3,709	Closed	-$10K	–	2145
2023 Q1	$10K	Buy	+3,709	New	+$13.3K	﹤0.01%	1348
2022 Q3	–	Sell	-3,286	Closed	-$17K	–	2322
2022 Q2	$17K	Buy	+3,286	New	+$20K	﹤0.01%	1364
2021 Q4	–	Sell	-4,517	Closed	-$54K	–	2263
2021 Q3	$54K	Sell	4,517 -10,738	-70%	-$211K	﹤0.01%	1263
2021 Q2	$411K	Sell	15,255 -3,779	-20%	-$92.1K	0.04%	564
2021 Q1	$548K	Buy	19,034 +4,701	+33%	+$163K	0.04%	478
2020 Q4	$224K	Buy	14,333 +11,535	+412%	+$133K	0.02%	789
2020 Q3	$27K	Sell	2,798 -2,460	-47%	-$63.9K	﹤0.01%	899
2020 Q2	$118K	Buy	+5,258	New	+$153K	0.01%	844
2018 Q3	–	Sell	-856	Closed	-$23K	–	2321
2018 Q2	$23K	Buy	856 +275	+47%	+$10.6K	﹤0.01%	1848
2018 Q1	$28K	Sell	581 -2,444	-81%	-$121K	﹤0.01%	1792
2017 Q4	$137K	Buy	3,025 +2,613	+634%	+$176K	0.01%	1817
2017 Q3	$28K	Buy	+412	New	+$25.9K	﹤0.01%	2298

Other funds holding GRCE

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Cantor Fitzgerald New York $9.23B AUM 74.49% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Virtu Financial's GRCE Position: Q2 2026 in Review

Virtu Financial opened a new position in Grace Therapeutics (GRCE) in Q2 2026: 10,166 shares worth $23K. The stake represents ﹤0.01% of the portfolio and ranks #1333 among its holdings. This is a return to the name: Virtu Financial previously reported a position in GRCE as recently as Q1 2023.

Virtu Financial first reported a position in GRCE in Q3 2017 and has held it in 13 quarters since. The position peaked at $548K in Q1 2021. 31 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

Virtu Financial held 10,166 shares of Grace Therapeutics worth $23K as of Q2 2026.
Grace Therapeutics was a new Virtu Financial position in Q2 2026.
Grace Therapeutics made up ﹤0.01% of Virtu Financial's portfolio in Q2 2026, its #1333 holding.
Virtu Financial first reported a position in Grace Therapeutics in Q3 2017 and has held it in 13 quarters since.
Virtu Financial's Grace Therapeutics position peaked at $548K in Q1 2021.
31 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.